These results suggested that the expression of ABCG2 and the SP may be regulated by PTEN through the PI3K/Akt pathway, which would be a potentially effective strategy for targeting CML stem cells. The gene discussed is PTEN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.